We studied acute and long-term effects of Clinofibrate on lipoprotein lipase (LPL) activity. In an acute administration study, Clinofibrate (400mg, single) was administered orally to 5 healthy subjects. On the other hand, in a long-term administration study, Clinofibrate (1, 200mg/day) was administered orally to 11 hyperlipidemic patients for about 4 to 8 weeks. We investigated postheparin lipolytic activity (PHLA), LPL and hepatic triglyceride lipase (HTGL) activity in the acute and long-term administration study, and serum lipid levels of all cases before and after Clinofibrate administration.
The results were as follows:
1. Acute administration study
Changes in LPL activity by Clinofibrate administration were variable.
2. Long-term administration study
1) Total cholesterol and triglyceride decreased significantly. High density lipoprotein-cholesterol was stable.
2) PHLA and LPL activity increased in 8 out of 11 patients. Decrease in total cholesterol and triglyceride was more marked in patients with the increased LPL activity than with decreased or unchanged. There is significant positive correlation between the percent increase in LPL activity and the percent decrease in triglyceride (r=0.77, p<0.05).
